Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Analysts note icotrokinra could be a competitive player in the UC market if it were to be approved due to its oral ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

The melanoma market is expected to witness sustained growth driven by continuous therapeutic innovation and wider patient access. Advances in immunotherapies and targeted treatments, along with ...

Johnson & Johnson’s (J&J) Tremfya (guselkumab) has received approval from the US Food and Drug Administration (FDA) for paediatric patients with plaque psoriasis and active psoriatic arthritis. This ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

PARIS — An investigational oral interleukin-23 (IL-23) inhibitor performed better and with fewer side effects than an established targeted oral agent for moderate-to-severe plaque psoriasis in two ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...

Some cells, such as immune cells, are highly mobile—they constantly remodel their shape, migrate toward a wound that needs to ...

The FDA approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya, Johnson & Johnson) for adults with moderately to severely active ulcerative colitis (UC). Guselkumab is the first and ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...